<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CUVPOSA- glycopyrrolate liquid </strong><br>Merz Pharmaceuticals, LLC<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use CUVPOSA<span class="Sup">®</span> safely and effectively.<br><br> See full prescribing information for CUVPOSA.<br><br> CUVPOSA (glycopyrrolate) oral solution<br> Initial U.S. Approval: 1961</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">CUVPOSA is an anticholinergic indicated to reduce chronic severe <span class="product-label-link" type="condition" conceptid="4266842" conceptname="Dribbling from mouth">drooling</span> in patients aged 3-16 years with neurologic conditions associated with problem <span class="product-label-link" type="condition" conceptid="4266842" conceptname="Dribbling from mouth">drooling</span> (e.g., <span class="product-label-link" type="condition" conceptid="4134120" conceptname="Cerebral palsy">cerebral palsy</span>). (<a href="#S1">1</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul>
<li> Initiate dosing at 0.02 mg/kg three times daily and titrate in increments of 0.02 mg/kg every 5-7 days, based on therapeutic response and adverse reactions. (<a href="#S2">2</a>)</li>
<li> Maximum recommended dose is 0.1 mg/kg three times daily, not to exceed 1.5-3 mg per dose based upon weight. (<a href="#S2">2</a>)</li>
<li> Administer as least one hour before or two hours after meals. (<a href="#S2">2</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">1 mg/5 mL, oral solution in 16 ounce bottles. (<a href="#S3">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul>
<li> Medical conditions that preclude anticholinergic therapy. (<a href="#S4">4</a>)</li>
<li> Concomitant use of solid dosage forms of potassium chloride. (<a href="#S4">4</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li> <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span> or intestinal pseudo-obstruction: May present as abnormal <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">distention</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. Assess patients for <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, particularly within 4-5 days of initial dosing or after a dose increase. (<a href="#S5.1">5.1</a>)</li>
<li> Incomplete mechanical <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">intestinal obstruction</span>: May present as <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. If obstruction is suspected, discontinue CUVPOSA and evaluate. (<a href="#S5.2">5.2</a>)</li>
<li> High ambient temperature: To reduce the risk of <span class="product-label-link" type="condition" conceptid="437744" conceptname="Heat exhaustion">heat prostration</span>, avoid <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">high temperatures</span>. (<a href="#S5.3">5.3</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most common adverse reactions (incidence ≥30%) are <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, and <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span>. (<a href="#S6">6</a>) </p>
<br><p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Merz Pharmaceuticals, LLC at 877-743-8454 or FDA at 1-800-FDA-1088 or <span class="Italics">www.fda.gov/medwatch. </span></span> </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul>
<li> Digoxin tablets: Use with glycopyrrolate can increase digoxin serum levels. Monitor patients and consider use of alternative dosage forms of digoxin. (<a href="#S7">7</a>)</li>
<li> Amantadine: Effects of glycopyrrolate may be increased with concomitant administration of amantadine. Consider decreasing the dose of glycopyrrolate during concomitant use. (<a href="#S7">7</a>)</li>
<li> Atenolol or metformin: Glycopyrrolate may increase serum levels of atenolol or metformin. Consider dose reduction when used with glycopyrrolate. (<a href="#S7">7</a>)</li>
<li> Haloperidol or levodopa: Glycopyrrolate may decrease serum levels of haloperidol or levodopa. Consider a dose increase when used with glycopyrrolate. (<a href="#S7">7</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul>
<li> Pediatric use: The safety and effectiveness of glycopyrrolate has not been established in patients less than 3 years of age. (<a href="#S8.4">8.4</a>)</li>
<li> <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span>: Use CUVPOSA with caution in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. (<a href="#S8.6">8.6</a>)</li>
</ul></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div><div></div></div>
<div><div></div></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 5/2013</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span> or Intestinal Pseudo-obstruction</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Incomplete Mechanical <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">Intestinal Obstruction</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 High Ambient Temperatures</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Operating Machinery or an Automobile</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Anticholinergic Drug Effects</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">CUVPOSA is indicated to reduce chronic severe <span class="product-label-link" type="condition" conceptid="4266842" conceptname="Dribbling from mouth">drooling</span> in patients aged 3 to 16 years with neurologic conditions associated with problem <span class="product-label-link" type="condition" conceptid="4266842" conceptname="Dribbling from mouth">drooling</span> (e.g., <span class="product-label-link" type="condition" conceptid="4134120" conceptname="Cerebral palsy">cerebral palsy</span>).</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First">CUVPOSA must be measured and administered with an accurate measuring device [see <span class="Italics"><a href="#S17">Patient Counseling Information (17)</a></span>].</p>
<p>Initiate dosing at 0.02 mg/kg orally three times daily and titrate in increments of 0.02 mg/kg every 5-7 days based on therapeutic response and adverse reactions. The maximum recommended dosage is 0.1 mg/kg three times daily not to exceed 1.5-3 mg per dose based upon weight. For greater detail, see<a href="#table1"> Table 1</a>.</p>
<p>During the four-week titration period, dosing can be increased with the recommended dose titration schedule while ensuring that the anticholinergic adverse events are tolerable. Prior to each increase in dose, review the tolerability of the current dose level with the patient's caregiver.</p>
<p>CUVPOSA should be dosed at least one hour before or two hours after meals.</p>
<p>The presence of high fat food reduces the oral bioavailability of CUVPOSA if taken shortly after a meal [see <span class="Italics"><a href="#S12.3">Clinical Pharmacology (12.3)</a></span>].</p>
<a name="table1"></a><table width="100%">
<caption><span>Table 1: Recommended Dose Titration Schedule (each dose to be given three times daily)</span></caption>
<col align="center" valign="top" width="8%">
<col align="center" valign="top" width="8%">
<col align="center" valign="top" width="9%">
<col align="center" valign="top" width="8%">
<col align="center" valign="top" width="9%">
<col align="center" valign="top" width="8%">
<col align="center" valign="top" width="9%">
<col align="center" valign="top" width="8%">
<col align="center" valign="top" width="9%">
<col align="center" valign="top" width="8%">
<col align="center" valign="top" width="8%">
<col align="center" valign="top" width="8%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="center" colspan="2">Weight</th>
<th class="Rrule" align="center" colspan="2">Dose Level 1</th>
<th class="Rrule" align="center" colspan="2">Dose Level 2</th>
<th class="Rrule" align="center" colspan="2">Dose Level 3</th>
<th class="Rrule" align="center" colspan="2">Dose Level 4</th>
<th class="Rrule" align="center" colspan="2">Dose Level 5</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="center">kg</th>
<th class="Rrule" align="center">lbs</th>
<th class="Rrule" align="center" colspan="2">(~0.02 mg/kg)</th>
<th class="Rrule" align="center" colspan="2">(~0.04 mg/kg)</th>
<th class="Rrule" align="center" colspan="2">(~0.06 mg/kg)</th>
<th class="Rrule" align="center" colspan="2">(~0.08 mg/kg)</th>
<th class="Rrule" align="center" colspan="2">(~0.1 mg/kg)</th>
</tr>
</thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="center">13-17</td>
<td class="Rrule" align="center">27-38</td>
<td class="Rrule" align="center">0.3 mg</td>
<td class="Rrule" align="center">1.5 mL</td>
<td class="Rrule" align="center">0.6 mg</td>
<td class="Rrule" align="center">3 mL</td>
<td class="Rrule" align="center">0.9 mg</td>
<td class="Rrule" align="center">4.5 mL</td>
<td class="Rrule" align="center">1.2 mg</td>
<td class="Rrule" align="center">6 mL</td>
<td class="Rrule" align="center">1.5 mg</td>
<td class="Rrule" align="center">7.5 mL</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">18-22</td>
<td class="Rrule" align="center">39-49</td>
<td class="Rrule" align="center">0.4 mg</td>
<td class="Rrule" align="center">2 mL</td>
<td class="Rrule" align="center">0.8 mL</td>
<td class="Rrule" align="center">4 mL</td>
<td class="Rrule" align="center">1.2 mg</td>
<td class="Rrule" align="center">6 mL</td>
<td class="Rrule" align="center">1.6 mg</td>
<td class="Rrule" align="center">8 mL</td>
<td class="Rrule" align="center">2.0 mg</td>
<td class="Rrule" align="center">10 mL</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">23-27</td>
<td class="Rrule" align="center">50-60</td>
<td class="Rrule" align="center">0.5 mg</td>
<td class="Rrule" align="center">2.5 mL</td>
<td class="Rrule" align="center">1.0 mg</td>
<td class="Rrule" align="center">5 mL</td>
<td class="Rrule" align="center">1.5 mg</td>
<td class="Rrule" align="center">7.5 mL</td>
<td class="Rrule" align="center">2.0 mg</td>
<td class="Rrule" align="center">10 mL</td>
<td class="Rrule" align="center">2.5 mg</td>
<td class="Rrule" align="center">12.5 mL</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">28-32</td>
<td class="Rrule" align="center">61-71</td>
<td class="Rrule" align="center">0.6 mg</td>
<td class="Rrule" align="center">3 mL</td>
<td class="Rrule" align="center">1.2 mg</td>
<td class="Rrule" align="center">6 mL</td>
<td class="Rrule" align="center">1.8 mg</td>
<td class="Rrule" align="center">9 mL</td>
<td class="Rrule" align="center">2.4 mg</td>
<td class="Rrule" align="center">12 mL</td>
<td class="Rrule" align="center">3.0 mg</td>
<td class="Rrule" align="center">15 mL</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">33-37</td>
<td class="Rrule" align="center">72-82</td>
<td class="Rrule" align="center">0.7 mg</td>
<td class="Rrule" align="center">3.5 mL</td>
<td class="Rrule" align="center">1.4 mg</td>
<td class="Rrule" align="center">7 mL</td>
<td class="Rrule" align="center">2.1 mg</td>
<td class="Rrule" align="center">10.5 mL</td>
<td class="Rrule" align="center">2.8 mg</td>
<td class="Rrule" align="center">14 mL</td>
<td class="Rrule" align="center">3.0 mg</td>
<td class="Rrule" align="center">15 mL</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">38-42</td>
<td class="Rrule" align="center">83-93</td>
<td class="Rrule" align="center">0.8 mg</td>
<td class="Rrule" align="center">4 mL</td>
<td class="Rrule" align="center">1.6 mg</td>
<td class="Rrule" align="center">8 mL</td>
<td class="Rrule" align="center">2.4 mg</td>
<td class="Rrule" align="center">12 mL</td>
<td class="Rrule" align="center">3.0 mg</td>
<td class="Rrule" align="center">15 mL</td>
<td class="Rrule" align="center">3.0 mg</td>
<td class="Rrule" align="center">15 mL</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">43-47</td>
<td class="Rrule" align="center">94-104</td>
<td class="Rrule" align="center">0.9 mg</td>
<td class="Rrule" align="center">4.5 mL</td>
<td class="Rrule" align="center">1.8 mg</td>
<td class="Rrule" align="center">9 mL</td>
<td class="Rrule" align="center">2.7 mg</td>
<td class="Rrule" align="center">13.5 mL</td>
<td class="Rrule" align="center">3.0 mg</td>
<td class="Rrule" align="center">15 mL</td>
<td class="Rrule" align="center">3.0 mg</td>
<td class="Rrule" align="center">15 mL</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center">≥48</td>
<td class="Rrule" align="center">≥105</td>
<td class="Rrule" align="center">1.0 mg</td>
<td class="Rrule" align="center">5 mL</td>
<td class="Rrule" align="center">2.0 mg</td>
<td class="Rrule" align="center">10 mL</td>
<td class="Rrule" align="center">3.0 mg</td>
<td class="Rrule" align="center">15 mL</td>
<td class="Rrule" align="center">3.0 mg</td>
<td class="Rrule" align="center">15 mL</td>
<td class="Rrule" align="center">3.0 mg</td>
<td class="Rrule" align="center">15 mL</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">CUVPOSA is available as a 1mg/5 mL clear, cherry-flavored solution for oral administration in 16 ounce bottles.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">CUVPOSA is contraindicated in:</p>
<ul>
<li> Patients with medical conditions that preclude anticholinergic therapy (e.g., <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">paralytic ileus</span>, unstable cardiovascular status in acute <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, severe <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>, toxic <span class="product-label-link" type="condition" conceptid="198465" conceptname="Megacolon, not Hirschsprung's">megacolon</span> complicating <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>, <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>).</li>
<li> Patients taking solid oral dosage forms of potassium chloride. The passage of potassium chloride tablets through the gastrointestinal (GI) tract may be arrested or delayed with coadministration of CUVPOSA.</li>
</ul>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span> or Intestinal Pseudo-obstruction</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span> is a common dose-limiting adverse reaction which sometimes leads to glycopyrrolate discontinuation [see <span class="Italics"><a href="#S6.1">Adverse Reactions (6.1)</a></span>]. Assess patients for <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, particularly within 4-5 days of initial dosing or after a dose increase. Intestinal pseudo-obstruction has been reported and may present as abdominal <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">distention</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Incomplete Mechanical <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">Intestinal Obstruction</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> may be an early symptom of incomplete mechanical <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">intestinal obstruction</span>, especially in patients with ileostomy or colostomy. If incomplete mechanical <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">intestinal obstruction</span> is suspected, discontinue treatment with CUVPOSA and evaluate for <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">intestinal obstruction</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3 High Ambient Temperatures</h2>
<p class="First">In the presence of high ambient temperature, <span class="product-label-link" type="condition" conceptid="437744" conceptname="Heat exhaustion">heat prostration</span> (<span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and <span class="product-label-link" type="condition" conceptid="4181404" conceptname="Heat stroke">heat stroke</span> due to decreased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>) can occur with the use of anticholinergic drugs such as CUVPOSA. Advise patients/caregivers to avoid exposure of the patient to hot or very warm environmental temperatures.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Operating Machinery or an Automobile</h2>
<p class="First">CUVPOSA may produce <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> or <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>. As appropriate for a given age, warn the patient not to engage in activities requiring mental alertness such as operating a motor vehicle or other machinery, or performing hazardous work while taking CUVPOSA.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Anticholinergic Drug Effects</h2>
<p class="First">Use CUVPOSA with caution in patients with conditions that are exacerbated by anticholinergic drug effects including:</p>
<ul>
<li> <span class="product-label-link" type="condition" conceptid="4080146" conceptname="Autonomic neuropathy">Autonomic neuropathy</span></li>
<li> <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">Renal disease</span></li>
<li> <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">Ulcerative colitis</span> – Large doses may suppress intestinal motility to the point of producing a <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">paralytic ileus</span> and for this reason may precipitate or aggravate "toxic <span class="product-label-link" type="condition" conceptid="198465" conceptname="Megacolon, not Hirschsprung's">megacolon</span>", a serious complication of the disease.</li>
<li> <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">Hyperthyroidism</span></li>
<li> Coronary heart disease, <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, cardiac <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachyarrhythmias</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, and <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span></li>
<li> <span class="product-label-link" type="condition" conceptid="4224004" conceptname="Hiatal hernia">Hiatal hernia</span> associated with <span class="product-label-link" type="condition" conceptid="30437" conceptname="Gastro-esophageal reflux disease with esophagitis">reflux esophagitis</span>, since anticholinergic drugs may aggravate this condition</li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following serious adverse reactions are described elsewhere in the labeling:</p>
<ul>
<li> <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span> or intestinal pseudo-obstruction [see <span class="Italics"><a href="#S5.1">Warnings and Precautions (5.1)</a></span>]</li>
<li> Incomplete mechanical <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">intestinal obstruction</span> [see <span class="Italics"><a href="#S5.2">Warnings and Precautions (5.2)</a></span>]</li>
</ul>
<p>The most common adverse reactions reported with CUVPOSA are <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, and <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p>The data described below reflect exposure to CUVPOSA in 151 subjects, including 20 subjects who participated in an 8-week placebo-controlled study (Study 1) and 137 subjects who participated in a 24-week open-label study (six subjects who received CUVPOSA in the placebo-controlled study and 131 new subjects).</p>
<p>Table 2 presents adverse reactions reported by ≥ 15% of CUVPOSA-treated subjects for the placebo-controlled clinical trial.</p>
<a name="table2"></a><table width="75%">
<caption><span>Table 2: Adverse Reactions Occurring in ≥ 15% of CUVPOSA-Treated Subjects and at a Greater Frequency than Placebo in Study 1</span></caption>
<col align="center" valign="top" width="40%">
<col align="center" valign="top" width="30%">
<col align="center" valign="top" width="30%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center"></th>
<th class="Rrule" align="center">CUVPOSA<br>(N=20)<br>n (%)</th>
<th class="Rrule" align="center">Placebo<br>(N=18)<br>n (%)</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="center"><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry Mouth</span></td>
<td class="Rrule" align="center">8 (40%)</td>
<td class="Rrule" align="center">2 (11%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Rrule" align="center">8 (40%)</td>
<td class="Rrule" align="center">2 (11%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td class="Rrule" align="center">7 (35%)</td>
<td class="Rrule" align="center">4 (22%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">Flushing</span></td>
<td class="Rrule" align="center">6 (30%)</td>
<td class="Rrule" align="center">3 (17%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">Nasal Congestion</span></td>
<td class="Rrule" align="center">6 (30%)</td>
<td class="Rrule" align="center">2 (11%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Rrule" align="center">3 (15%)</td>
<td class="Rrule" align="center">1 (6%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span></td>
<td class="Rrule" align="center">3 (15%)</td>
<td class="Rrule" align="center">1 (6%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper Respiratory Tract Infection</span></td>
<td class="Rrule" align="center">3 (15%)</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center"><span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">Urinary Retention</span></td>
<td class="Rrule" align="center">3 (15%)</td>
<td class="Rrule" align="center">0</td>
</tr>
</tbody>
</table>
<p>The following adverse reactions occurred at a rate of &lt;2% of patients receiving CUVPOSA in the open-label study.</p>
<dl>
<dt> </dt>
<dd>Gastrointestinal: Abdominal <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">distention</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4152197" conceptname="Stomach ache">stomach discomfort</span>, <span class="product-label-link" type="condition" conceptid="4039954" conceptname="Cheilosis">chapped lips</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="4309379" conceptname="Retching">retching</span>, dry tongue</dd>
<dt> </dt>
<dd>General Disorders: <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">Irritability</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span>: <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span>, <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>, <span class="product-label-link" type="condition" conceptid="4094909" conceptname="Tracheostomy sepsis">tracheostomy infection</span>, <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span>, <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span></dd>
<dt> </dt>
<dd>Investigations: Heart rate increase</dd>
<dt> </dt>
<dd>Metabolism and Nutrition: <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">Dehydration</span></dd>
<dt> </dt>
<dd>Nervous System: <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsion</span>, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">dysgeusia</span>, <span class="product-label-link" type="condition" conceptid="378165" conceptname="Nystagmus">nystagmus</span></dd>
<dt> </dt>
<dd>Psychiatric: <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">Agitation</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, abnormal behavior, <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggression</span>, <span class="product-label-link" type="condition" conceptid="4136768" conceptname="Crying">crying</span>, <span class="product-label-link" type="condition" conceptid="433752" conceptname="Impulse control disorder">impulse control disorder</span>, moaning, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">mood altered</span></dd>
<dt> </dt>
<dd>Respiratory: Increased viscosity of bronchial secretion, <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span>, <span class="product-label-link" type="condition" conceptid="4171214" conceptname="Nasal mucosa dry">nasal dryness</span></dd>
<dt> </dt>
<dd>Skin: <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">Dry skin</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span></dd>
<dt> </dt>
<dd>Vascular: <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">Pallor</span></dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<p class="First">The following adverse reactions have been identified during postapproval use of other formulations of glycopyrrolate for other indications. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p>Additional adverse reactions identified during postapproval use of glycopyrrolate tablets include: <span class="product-label-link" type="condition" conceptid="4289517" conceptname="Loss of taste">loss of taste</span> and suppression of lactation.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="S7"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1"></a><p></p>
<p class="First"><span class="Underline">Drugs Affected by Reduced GI Transit Time</span></p>
<p>Glycopyrrolate reduces GI transit time, which may result in altered release of certain drugs when formulated in delayed- or controlled-release dosage forms.</p>
<ul>
<li> The passage of potassium chloride tablets through the GI tract may be arrested or delayed with coadministration of glycopyrrolate. Solid dosage forms of potassium chloride are contraindicated [see <span class="Italics"><a href="#S4">Contraindications (4)</a></span>].</li>
<li> Digoxin administered as slow dissolution oral tablets may have increased serum levels and enhanced action when administered with glycopyrrolate. Monitor patients receiving slow dissolution digoxin for increased action if glycopyrrolate is coadministered regularly. Consider the use of other oral dosage forms of digoxin (e.g., elixir or capsules).</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2"></a><p></p>
<p class="First"><span class="Underline">Amantadine</span></p>
<p>The anticholinergic effects of glycopyrrolate may be increased with concomitant administration of amantadine. Consider decreasing the dose of glycopyrrolate during coadministration of amantadine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3"></a><p></p>
<p class="First"><span class="Underline">Drugs Whose Plasma Levels May be Increased by Glycopyrrolate</span></p>
<p>Coadministration of glycopyrrolate may result in increased levels of certain drugs.</p>
<ul>
<li> Atenolol's bioavailability may be increased with coadministration of glycopyrrolate. A reduction in the atenolol dose may be needed.</li>
<li> Metformin plasma levels may be elevated with coadministration of glycopyrrolate, increasing metformin's pharmacologic and toxic effects. Monitor clinical response to metformin with concomitant glycopyrrolate administration; consider a dose reduction of metformin if warranted.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.4"></a><p></p>
<p class="First"><span class="Underline">Drugs Whose Plasma Levels May be Decreased by Glycopyrrolate</span></p>
<p>Coadministration of glycopyrrolate may result in decreased levels of certain drugs.</p>
<ul>
<li> Haloperidol's serum level may be decreased when coadministered with glycopyrrolate, resulting in worsening of schizophrenic symptoms, and development of <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span>. Closely monitor patients if coadministration cannot be avoided.</li>
<li> Levodopa's therapeutic effect may be reduced with glycopyrrolate administration. Consider increasing the dose of levodopa.</li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-8.1.1"></a><p></p>
<p class="First"><span class="Underline">Pregnancy Category C</span></p>
<p>There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted with glycopyrrolate. It is also not known whether glycopyrrolate can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. CUVPOSA should be given to a pregnant woman only if clearly needed.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="S8.3"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when CUVPOSA is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">CUVPOSA was evaluated for chronic severe <span class="product-label-link" type="condition" conceptid="4266842" conceptname="Dribbling from mouth">drooling</span> in patients aged 3-16 years with neurologic conditions associated with problem <span class="product-label-link" type="condition" conceptid="4266842" conceptname="Dribbling from mouth">drooling</span>. CUVPOSA has not been studied in subjects under the age of 3 years.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="S8.5"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Clinical studies of CUVPOSA did not include subjects aged 65 and over.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.6"></a><a name="section-8.5"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Because glycopyrrolate is largely renally eliminated, CUVPOSA should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> [see <span class="Italics"><a href="#S12.3">Clinical Pharmacology (12.3)</a></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="S10"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">Because glycopyrrolate is a quaternary amine which does not easily cross the blood-brain barrier, symptoms of glycopyrrolate overdosage are generally more peripheral in nature rather than central compared to other anticholinergic agents. In case of accidental <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, therapy may include:</p>
<ul>
<li> Maintain an open airway, providing ventilation as necessary.</li>
<li> Managing any acute conditions such as <span class="product-label-link" type="condition" conceptid="4178904" conceptname="Body temperature above reference range">hyperthermia</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> and or <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> as applicable, and managing any jerky myoclonic movements or <span class="product-label-link" type="condition" conceptid="4181630" conceptname="Choreoathetosis">choreoathetosis</span> which may lead to <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> in some cases of anticholinergic overdosage.</li>
<li> Administering a quaternary ammonium anticholinesterase such as neostigmine to help alleviate-peripheral anticholinergic effects such as anticholinergic induced <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">ileus</span>.</li>
<li> Administering activated charcoal orally as appropriate.</li>
</ul>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">CUVPOSA is an anticholinergic drug available as an oral solution containing 1 mg glycopyrrolate per 5 mL. The chemical name for glycopyrrolate is pyrrolidinium, 3-[(cyclopentylhydroxyphenylacetyl) oxy]-1,1-dimethyl-,bromide. The chemical structure is:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d200bd44-9856-4104-a29e-a4cca3db6737&amp;name=cuvposa-01.jpg"></div>
<p>The empirical formula for CUVPOSA is C<span class="Sub">19</span>H<span class="Sub">28</span>BrNO<span class="Sub">3</span> and the molecular weight is 398.33. The inactive ingredients in CUVPOSA are: citric acid, glycerin, natural and artificial cherry flavor, methylparaben, propylene glycol, propylparaben, saccharin sodium, sodium citrate, sorbitol solution, and purified water.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="S12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Glycopyrrolate is a competitive inhibitor of acetylcholine receptors that are located on certain peripheral tissues, including salivary glands. Glycopyrrolate indirectly reduces the rate of <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">salivation</span> by preventing the stimulation of these receptors.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="S12.2"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">Glycopyrrolate inhibits the action of acetylcholine on salivary glands thereby reducing the extent of <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">salivation</span>.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="S12.3"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.1"></a><p></p>
<p class="First"><span class="Underline">Absorption</span></p>
<p>In a parallel study of children (n=6 per group) aged 7-14 years undergoing intraocular surgery, subjects received either intravenous (IV) or oral glycopyrrolate as a premedication. The mean absolute bioavailability of oral glycopyrrolate tablets was low (approximately 3%) and highly variable among subjects (range 1.3 to 13.3%). A similar pattern of low and variable relative bioavailability is seen in adults.</p>
<p>Analysis of population pharmacokinetic data from normal adults and children with <span class="product-label-link" type="condition" conceptid="4134120" conceptname="Cerebral palsy">cerebral palsy</span> associated chronic moderate to severe <span class="product-label-link" type="condition" conceptid="4266842" conceptname="Dribbling from mouth">drooling</span> failed to demonstrate linear pharmacokinetics across the dose range. In the same analysis, population estimates of the apparent oral clearance (scaled by weight in children and adults) ranged from 5.28 - 38.95 L/hr/kg for healthy adults and 8.07 - 25.65 L/hr/kg for patients with <span class="product-label-link" type="condition" conceptid="4134120" conceptname="Cerebral palsy">cerebral palsy</span>, a reflection of the low and highly variable oral bioavailability of glycopyrrolate.</p>
<p>Absorption of CUVPOSA (fasting) was compared to that of a marketed glycopyrrolate oral tablet. The C<span class="Sub">max</span> after oral solution administration was 23% lower compared to tablet administration and AUC<span class="Sub">0-inf</span> was 28% lower after oral solution administration. Mean C<span class="Sub">max</span> after oral solution administration in the fasting state was 0.318 ng/mL, and mean AUC<span class="Sub">0-24 </span>was 1.74 ng.hr/mL. Mean time to maximum plasma concentration for CUVPOSA was 3.1 hours, and mean plasma half-life was 3.0 hours.</p>
<p>In healthy adults, a high fat meal was shown to significantly affect the absorption of glycopyrrolate oral solution (10 mL, 1 mg/5 mL). The mean C<span class="Sub">max </span>under fed high fat meal conditions was approximately 74% lower than the C<span class="Sub">max</span> observed under fasting conditions. Similarly, mean AUC<span class="Sub">0-T </span>was reduced by about 78% by the high fat meal compared with the fasting AUC<span class="Sub">0-T</span>. A high fat meal markedly reduces the oral bioavailability of CUVPOSA. Therefore, CUVOPSA should be dosed at least one hour before or two hours after meals. Pharmacokinetic results (mean ± SD) are described in Table 3.</p>
<a name="table3"></a><table width="80%">
<caption><span>Table 3: Pharmacokinetic Parameters (mean±SD) for CUVPOSA, Fasting and Fed, in Healthy Adults</span></caption>
<col align="left" valign="top" width="16%">
<col align="center" valign="top" width="17%">
<col align="center" valign="top" width="17%">
<col align="center" valign="top" width="17%">
<col align="center" valign="top" width="17%">
<col align="center" valign="top" width="16%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center">C<span class="Sub">max</span><br>(ng/mL)</th>
<th class="Rrule" align="center">T<span class="Sub">max</span><br>(hrs)</th>
<th class="Rrule" align="center">AUC<span class="Sub">0-T</span><br>(ng∙hr/mL)</th>
<th class="Rrule" align="center">AUC<span class="Sub">0-Inf</span><br>(ng∙hr/mL)</th>
<th class="Rrule" align="center">T<span class="Sub">1/2</span><br>(hrs)</th>
</tr></thead>
<tfoot><tr><td colspan="6" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>n=35</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="Bold">Fasting<br>(n=37)</span></td>
<td class="Rrule" align="center">0.318 ± 0.190</td>
<td class="Rrule" align="center">3.10 ± 1.08</td>
<td class="Rrule" align="center">1.74 ± 1.07</td>
<td class="Rrule" align="center">1.81 ± 1.09</td>
<td class="Rrule" align="center">3.0 ± 1.2</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class="Bold">Fed<br>(n=36)</span></td>
<td class="Rrule" align="center">0.084 ± 0.081</td>
<td class="Rrule" align="center">2.60 ± 1.12</td>
<td class="Rrule" align="center">0.38 ± 0.14</td>
<td class="Rrule" align="center">0.46 ± 0.13<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>
</td>
<td class="Rrule" align="center">3.2 ± 1.1<a href="#footnote-1" class="Sup">*</a>
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.2"></a><p></p>
<p class="First"><span class="Underline">Distribution</span></p>
<p>After IV administration, glycopyrrolate has a mean volume of distribution in children aged 1 to 14 years of approximately 1.3 to 1.8 L/kg, with a range from 0.7 to 3.9 L/kg. In adults aged 60-75 years, the volume of distribution was lower (0.42 L/kg +/- 0.22).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.3"></a><p></p>
<p class="First"><span class="Underline">Metabolism</span></p>
<p>In adult patients who underwent surgery for <span class="product-label-link" type="condition" conceptid="4098112" conceptname="Biliary sludge">cholelithiasis</span> and were given a single IV dose of tritiated glycopyrrolate, approximately 85% of total radioactivity was excreted in urine and &lt;5% was present in T-tube drainage of bile. In both urine and bile, &gt;80% of the radioactivity corresponded to unchanged drug. These data suggest a small proportion of IV glycopyrrolate is excreted as one or more metabolites.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.4"></a><p></p>
<p class="First"><span class="Underline">Elimination</span></p>
<p>Approximately 65-80% of an IV glycopyrrolate dose was eliminated unchanged in urine in adults. In two studies, after IV administration to pediatric patients ages 1-14 years, mean clearance values ranged from 1.01- 1.41 L/kg/hr (range 0.32 -2.22 L/kg/hr). In adults, IV clearance values were 0.54 ± 0.14 L/kg/hr.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5"></a><p></p>
<p class="First"><span class="Underline">Pediatrics</span></p>
<p>The estimated apparent clearance of glycopyrrolate from a population pharmacokinetic analysis (scaled by weight in children and adults) of oral and IV data was found to be 13.2 L/hr/kg or 92.7 L/hr for a typical 70 kg subject. In the same population based analysis, gender was not identified as having an effect on either glycopyrrolate clearance or systemic exposure.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.6"></a><p></p>
<p class="First"><span class="Underline">Gender</span></p>
<p>Population pharmacokinetic evaluation of adults and children administered IV or oral glycopyrrolate identified no effect of gender on glycopyrrolate clearance or systemic exposure.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.7"></a><p></p>
<p class="First"><span class="Underline">Race</span></p>
<p>The pharmacokinetics of glycopyrrolate by race have not been characterized.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.8"></a><p></p>
<p class="First"><span class="Underline">Elderly</span></p>
<p>Glycopyrrolate pharmacokinetics have not been characterized in the elderly.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.9"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></p>
<p>In one study, glycopyrrolate 4 mcg/kg was administered intravenously in uremic patients undergoing renal transplantation surgery. Mean AUC (10.6 mcg∙h/L), mean plasma clearance (0.43 L/hr/kg) and mean 3-hour urinary excretion (0.7%) for glycopyrrolate were significantly different than those of control patients (3.73 µg∙h/L, 1.14 L/hr/kg, and 50%, respectively). These results suggest that elimination of glycopyrrolate is severely impaired in patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.10"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></p>
<p>Glycopyrrolate is largely renally eliminated. The pharmacokinetics of glycopyrrolate have not been evaluated in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="S13"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="S13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Long-term animal studies have not been performed to evaluate the carcinogenic potential of glycopyrrolate.</p>
<p>Glycopyrrolate did not elicit any genotoxic effects in the Ames mutagenicity assay, the human lymphocyte chromosome aberration assay, or the micronucleus assay.</p>
<p>Glycopyrrolate was assessed for effects on fertility or general reproductive function in rats.  Rats of both genders received glycopyrrolate at dosages up to 100 mg/kg/day via oral gavage (approximately 50 times the maximum recommended human dose, when comparing on the basis of body surface area estimates).  No treatment-related effects on fertility or reproductive parameters of both genders were observed in this study.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">CUVPOSA was evaluated in a multi-center, randomized, double-blind, placebo-controlled, parallel, eight-week study for the control of pathologic <span class="product-label-link" type="condition" conceptid="4266842" conceptname="Dribbling from mouth">drooling</span> in children (Study 1). The study enrolled 38 subjects aged 3-23 years; thirty-six subjects were aged 3-16 years and two patients were greater than 16 years. The subjects were male or female, weighed at least 13 kg (27 lbs), and had <span class="product-label-link" type="condition" conceptid="4134120" conceptname="Cerebral palsy">cerebral palsy</span>, <span class="product-label-link" type="condition" conceptid="440389" conceptname="Mental retardation">mental retardation</span>, or another neurologic condition associated with problem <span class="product-label-link" type="condition" conceptid="4266842" conceptname="Dribbling from mouth">drooling</span> defined as <span class="product-label-link" type="condition" conceptid="4266842" conceptname="Dribbling from mouth">drooling</span> in the absence of treatment so that clothing became damp on most days (approximately five to seven days per week). Subjects were randomized in a 1:1 fashion to receive CUVPOSA or placebo. Doses of study medication were titrated over a 4-week period to optimal response beginning at 0.02 mg/kg three times a day increasing doses in increments of approximately 0.02 mg/kg three times per day every 5-7 days, not to exceed the lesser of approximately 0.1 mg/kg three times per day or 3 mg three times per day.</p>
<p>Subjects were evaluated on the 9-point modified Teacher's <span class="product-label-link" type="condition" conceptid="4266842" conceptname="Dribbling from mouth">Drooling</span> Scale (mTDS), which is presented below. The mTDS evaluations were recorded by parents/caregivers 3 times daily approximately two hours post-dose on evaluation days during pre-treatment baseline and at Weeks 2, 4, 6 and 8 of therapy.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.1"></a><p></p>
<p class="First"><span class="Underline">Modified Teacher's <span class="product-label-link" type="condition" conceptid="4266842" conceptname="Dribbling from mouth">Drooling</span> Scale</span></p>
<p>1= Dry: never drools<br>2= Mild: only the lips are wet; occasionally<br>3= Mild: only the lips are wet; frequently<br>4= Moderate: wet on lips and chin; occasionally<br>5= Moderate: wet on the lips and chin; frequently<br>6= Severe: drools to the extent that clothing becomes damp; occasionally<br>7= Severe: drools to the extent that clothing becomes damp; frequently<br>8= Profuse: clothing, hands, tray, and objects became wet; occasionally<br>9= Profuse: clothing, hands, tray, and objects became wet; frequently</p>
<p>Responders were defined as subjects with at least a 3-point reduction in mean daily mTDS scores from baseline to Week 8. Table 4 presents the proportion of responders at Week 8 and Figure 1 presents the mean mTDS values from baseline through Week 8.</p>
<a name="table4"></a><table width="75%">
<caption><span>Table 4: Percentage of Responders at Week 8</span></caption>
<col align="center" valign="top" width="50%">
<col align="center" valign="top" width="50%">
<thead><tr class="First Last">
<th class="Lrule" align="center">CUVPOSA GROUP<br>(N=20)</th>
<th class="Lrule Rrule" align="center">Placebo Group<br>(N=18)</th>
</tr></thead>
<tbody><tr class="First Last">
<td class="Lrule" align="center">15/20 (75%)</td>
<td class="Lrule Rrule" align="center">2/18 (11%)</td>
</tr></tbody>
</table>
<table class="Noautorules" width="100%">
<caption><span>Figure 1. Mean (± 2 Standard Errors) mDTS Scores</span></caption>
<col align="center" valign="top" width="100%">
<tbody class="Headless"><tr><td align="center"><img alt="Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d200bd44-9856-4104-a29e-a4cca3db6737&amp;name=cuvposa-02.jpg"></td></tr></tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="S16"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">NDC 0259-0501-16; 1 mg/5mL clear, cherry-flavored solution; 16 oz. bottle.</p>
<div class="Section" data-sectionCode="44425-7">
<a name="section-14.1"></a><p></p>
<p class="First">Store at room temperature 20° - 25°C (68° - 77°F); excursions permitted to 15° - 30°C (59° - 86°F) [See USP Controlled Room Temperature].</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="S17"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First"><span class="Italics">See </span><span class="Italics"><a href="#PI">FDA-Approved Patient Labeling</a></span></p>
<ul>
<li> Advise parent/caregivers to measure CUVPOSA with an accurate measuring device. A household teaspoon is not an accurate measuring device. Patients/caregivers should use a dosing cup available in pharmacies to accurately measure the correct milliliter dose for the patient. An oral syringe, also available in pharmacies, should be used to dispense CUVPOSA into the child's mouth from the cup. A pharmacist can recommend an appropriate measuring device and can provide instructions for measuring the correct dose.</li>
<li> Administering CUVPOSA with a high fat meal substantially reduces the amount of glycopyrrolate absorbed. Administer CUVPOSA at least one hour before or two hours after meals.</li>
<li> CUVPOSA is started at a low dose and gradually titrated over a period of weeks based on therapeutic response and adverse reactions. Parents/caregivers should not increase the dose without the physician's permission.</li>
<li> Common adverse reactions from CUVPOSA include overly <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span> of the skin or face, and <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>. Side effects can sometimes be difficult to detect in some patients with neurologic problems who cannot adequately communicate how they feel. If side effects become troublesome after increasing a dose, decrease the dose to the prior one and contact your physician.</li>
<li> <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span> is the most common side effect of glycopyrrolate, and if <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> occurs, stop administering glycopyrrolate to the patient and call their healthcare practitioner.</li>
<li> Inability of the patient to urinate, dry diapers or undergarments, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span> or <span class="product-label-link" type="condition" conceptid="4136768" conceptname="Crying">crying</span> may be signs of <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>, and if <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span> occurs, parents/caregivers should stop administering glycopyrrolate and call their healthcare practitioner.</li>
<li> If the patient develops a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span> or an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>, parents/caregivers should stop administering glycopyrrolate and call their healthcare practitioner as this could be a sign of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to this product.</li>
<li> Drugs like glycopyrrolate can reduce <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, and if the patient is in a hot environment and <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span> of the skin occurs this may be due to overheating. Patients/caregivers should be advised to avoid exposure of the patient to hot or very warm environmental temperatures to avoid overheating and the possibility of <span class="product-label-link" type="condition" conceptid="437744" conceptname="Heat exhaustion">heat exhaustion</span> or <span class="product-label-link" type="condition" conceptid="4181404" conceptname="Heat stroke">heat stroke</span>.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16"></a><p></p>
<p class="First">Manufactured by:<br>Mikart, Inc.<br>Atlanta, GA 30318</p>
<p>Manufactured for:<br>Merz Pharmaceuticals, LLC<br>Greensboro, NC 27410</p>
<p>© 2013 Merz Pharmaceuticals, LLC<br>CUVPOSA® is a registered trademark of Merz Pharmaceuticals, LLC</p>
<p>GLY-PI-05</p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="PI"></a><a name="section-17"></a><p></p>
<p class="First"><span class="Bold">PATIENT and CAREGIVER INFORMATION</span></p>
<p><span class="Bold">CUVPOSA (glycopyrrolate) Oral Solution</span></p>
<p>Please read the Patient and Caregiver Information that comes with CUVPOSA before you start giving it to your child, and each time you get a refill. This leaflet does not take the place of talking with your doctor about your child's medical condition or treatment.</p>
<p><span class="Bold">What is CUVPOSA?</span></p>
<p>CUVPOSA is a prescription medicine used in children with medical conditions that cause too much (abnormal) <span class="product-label-link" type="condition" conceptid="4266842" conceptname="Dribbling from mouth">drooling</span>.</p>
<p><span class="Bold">Who should not take CUVPOSA?</span></p>
<p>Do not give CUVPOSA to anyone who:</p>
<ul class="Disc">
<li>has problems urinating</li>
<li>has a bowel problem called <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">paralytic ileus</span></li>
<li>lacks normal bowel tone or <span class="product-label-link" type="condition" conceptid="4200706" conceptname="Tension">tension</span></li>
<li>has severe <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span> or certain other serious bowel problems with severe <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span></li>
<li>has <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span></li>
</ul>
<p><span class="Bold">What should I tell my doctor before giving CUVPOSA to my child?</span></p>
<p>Tell your doctor if your child:</p>
<ul class="Disc">
<li>has any allergies</li>
<li>has any stomach or bowel problems, including <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span></li>
<li>has any problems with <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span></li>
<li>has thyroid problems</li>
<li>has high blood pressure</li>
<li>has heart problems or abnormal heart beats</li>
<li>has a <span class="product-label-link" type="condition" conceptid="4224004" conceptname="Hiatal hernia">hiatal hernia</span> with <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">gastroesophageal reflux disease</span> (<span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>)</li>
<li>has any eye problems</li>
<li>has any problems urinating</li>
<li>has any other medical conditions</li>
<li>is pregnant or plans to become pregnant. It is not known if CUVPOSA can harm an unborn baby.</li>
<li>is breastfeeding or plans to breastfeed. It is not known if CUVPOSA passes into breast milk and if it can harm the baby.</li>
</ul>
<p><span class="Bold">Tell your doctor about all of the medicines that your child takes</span>, including prescription and non-prescription medicines, vitamins, and herbal supplements. Some medicine may affect the way CUVPOSA works, and CUVPOSA may affect how some other medicines work.</p>
<p><span class="Bold">How should I give CUVPOSA?</span></p>
<ul class="Disc">
<li> Give CUVPOSA exactly as prescribed by your child's doctor.</li>
<li> Give CUVPOSA 1 hour before or 2 hours after meals.</li>
<li> Your doctor will tell you how much (milliliters or mLs) of CUVPOSA to give your child.</li>
<li> Do not change the dose of CUVPOSA unless your doctor tells you to.</li>
<li> You must measure the dose of CUVPOSA before giving it to your child. Use a special marked dose measuring cup (available at most pharmacies) to measure the right dose of CUVPOSA.</li>
<li> To help make sure that your child swallows the dose, you should use an oral syringe to give the child each dose of CUVPOSA, after you measure the dose needed with a dose measuring cup. Oral syringes are also available at most pharmacies.</li>
<li> If you have questions about how to measure the dose or how to use an oral syringe, ask your pharmacist or doctor.</li>
<li> The dose of CUVPOSA that is needed to control <span class="product-label-link" type="condition" conceptid="4266842" conceptname="Dribbling from mouth">drooling</span> may be different for each child. CUVPOSA is usually started at a low dose, and slowly increased as directed by your doctor. This slow increase in dose continues until the best dose for your child is reached, to control <span class="product-label-link" type="condition" conceptid="4266842" conceptname="Dribbling from mouth">drooling</span>.</li>
<li> During this time it is important to stay in close contact with your child's doctor, and tell the doctor about any side effects that your child has. See "<a href="#sidefx">What are the possible side effects of CUVPOSA</a>?"</li>
</ul>
<p><span class="Bold">What should I avoid while taking CUVPOSA?</span></p>
<ul class="Disc">
<li> CUVPOSA may cause <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span> or <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>. Do not drive a car, operate heavy machinery, or do other dangerous activities while taking CUVPOSA.</li>
<li> Avoid overheating. See "<a href="#sidefx">What are the possible side effects of CUVPOSA</a>?"</li>
</ul>
<p><a name="sidefx"></a><span class="Bold">What are possible side effects of CUVPOSA?</span></p>
<p>CUVPOSA can cause serious side effects including:</p>
<ul class="Disc">
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span>. </span><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span> is common with CUVPOSA. Tell your doctor if your child <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> with bowel movements, goes longer between bowel movements, cannot have a bowel movement, or their stomach is firm and large. The dose of CUVPOSA may need to be decreased or stopped.</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> and intestinal blockage.</span> <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> can be an early symptom of a blockage in the intestine. This is especially true if you child has a colostomy or ileostomy. Tell your doctor if your child has any <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> while taking CUVPOSA.</li>
<li>
<span class="Bold">Problems with control of body temperature (overheating or <span class="product-label-link" type="condition" conceptid="4181404" conceptname="Heat stroke">heat stroke</span>). </span>CUVPOSA can cause your child to sweat less. Your child can become overheated, and develop <span class="product-label-link" type="condition" conceptid="4181404" conceptname="Heat stroke">heat stroke</span> if they are in an area that is very hot. Avoid overheating. Call your doctor right away if your child becomes sick and has any of these symptoms of heatstroke:<ul class="Disc">
<li> hot, red skin</li>
<li> decreased alertness or passing out (<span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">unconsciousness</span>)</li>
<li> fast, weak pulse</li>
<li> fast, <span class="product-label-link" type="condition" conceptid="4302536" conceptname="Shallow breathing">shallow breathing</span></li>
<li> increased body temperature (<span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>)</li>
</ul>
</li>
</ul>
<p>The most common side effects of CUVPOSA include:</p>
<ul class="Disc">
<li> <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span></li>
<li> <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></li>
<li> <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span> of the face or skin</li>
<li> <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span></li>
<li> <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></li>
<li> swollen sinuses (<span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>)</li>
<li> <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span></li>
<li> problem urinating, difficulty starting urination</li>
</ul>
<p>Tell your doctor if your child has any side effect that concerns you or that does not go away. These are not all the possible side effects of CUVPOSA.</p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">How should I store CUVPOSA?</span></p>
<p>Store CUVPOSA between 68°F to 77°F (20°C to 25°C).</p>
<p><span class="Bold">Keep CUVPOSA out of the reach of children.</span></p>
<p><span class="Bold">General information and CUVPOSA:</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use CUVPOSA for a condition for which it was not prescribed. Do not give CUVPOSA to other people even if they have the same condition. It may harm them.</p>
<p>This leaflet summarizes the most important information about CUVPOSA. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about CUVPOSA that is written for health professionals.</p>
<p>For more information, go to: <span class="Underline">www.cuvposa.com</span> or call 877-743-8454.</p>
<p><span class="Bold">What are the ingredients in CUVPOSA?</span></p>
<p>Active Ingredient: glycopyrrolate</p>
<p>Inactive Ingredients: citric acid, glycerin, natural and artificial cherry flavor, methylparaben, propylene glycol, propylparaben, saccharin sodium, sodium citrate, sorbitol solution, and purified water</p>
<p>Issued May 2011</p>
<p>Manufactured by:<br>Mikart, Inc.<br>Atlanta, GA 30318</p>
<p>Manufactured for:<br>Merz Pharmaceuticals, LLC<br>Greensboro, NC 27410</p>
<p>© 2013 Merz Pharmaceuticals, LLC<br>CUVPOSA® is a registered trademark of Merz Pharmaceuticals, LLC</p>
<p>GLY-PPI-05<br>Rev 05/2013</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-18"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 473 mL Bottle Carton</span></p>
<p><span class="Bold">NDC: 0259-0501-16</span></p>
<p>16 fl. oz.<br>(473 mL)</p>
<p><span class="Bold">Cuvposa</span><span class="Sup">®</span><br><span class="Bold">(glycopyrrolate) oral solution<br>1 mg/5 mL<br>(0.2 mg/mL)</span></p>
<p><span class="Bold">Rx Only<br>For Oral Use Only</span></p>
<p>Manufactured for:<br>Merz Pharmaceuticals, LLC<br>Greensboro, NC 27410</p>
<p>Manufactured by:<br>Mikart, Inc.<br>Atlanta, GA 30318</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 473 mL Bottle Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d200bd44-9856-4104-a29e-a4cca3db6737&amp;name=cuvposa-03.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CUVPOSA 		
					</strong><br><span class="contentTableReg">glycopyrrolate liquid</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0259-0501</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>glycopyrrolate</strong> (GLYCOPYRRONIUM) </td>
<td class="formItem">glycopyrrolate</td>
<td class="formItem">1 mg  in 5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Sorbitol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Glycerin</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Propylene Glycol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Methylparaben</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Propylparaben</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Citric Acid Monohydrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Sodium Citrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Saccharin Sodium</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Water</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">    </td>
<td class="formLabel">Score</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">CHERRY</td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0259-0501-16</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">473 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022571</td>
<td class="formItem">01/01/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Merz Pharmaceuticals, LLC
							(126209282)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Mikart, Inc.</td>
<td class="formItem"></td>
<td class="formItem">013322387</td>
<td class="formItem">MANUFACTURE(0259-0501)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Mikart, Inc.</td>
<td class="formItem"></td>
<td class="formItem">030034847</td>
<td class="formItem">PACK(0259-0501)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 5/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>22138167-a846-49f8-b669-a115c483c3ae</div>
<div>Set id: d200bd44-9856-4104-a29e-a4cca3db6737</div>
<div>Version: 4</div>
<div>Effective Time: 20130528</div>
</div>
</div> <div class="DistributorName">Merz Pharmaceuticals, LLC</div></p>
</body></html>
